Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Zolmitriptan clinical studies.

E A MacGregor¹

¹The City of London Migraine Clinic, London, UK.

Drugs of Today (Barcelona, Spain : 1998)

|January 27, 2004

Summary

This summary is machine-generated.

Zolmitriptan effectively treats migraine within 45 minutes. This selective serotonin receptor agonist shows a clear dose-response relationship and is safe for most patients, with future formulations offering more choices.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Aids to management of headache disorders in primary care (2nd edition) : on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache.

The journal of headache and pain·2019

Same author

The headache under-response to treatment (HURT) questionnaire, an outcome measure to guide follow-up in primary care: development, psychometric evaluation and assessment of utility.

The journal of headache and pain·2018

Same author

Association study of the calcitonin gene-related polypeptide-alpha (CALCA) and the receptor activity modifying 1 (RAMP1) genes with migraine.

Gene·2012

Same author

Studies of cereal alpha-amylases using cloned dna.

Critical reviews in biotechnology·2010

Same author

Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks.

Cephalalgia : an international journal of headache·2009

Same author

Estrogen replacement and migraine.

Maturitas·2009

Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023

See all related articles

Area of Science:

Pharmacology
Neurology
Clinical Therapeutics

Background:

Migraine is a debilitating neurological disorder.
Selective 5-HT(1B/D) agonists represent a therapeutic class for acute migraine treatment.

Purpose of the Study:

To evaluate the efficacy and safety of zolmitriptan for acute migraine treatment.
To establish the dose-response relationship for oral zolmitriptan formulation.

Main Methods:

Dose-finding studies were conducted to determine optimal dosing.
Clinical trials assessed efficacy across various migraine types.
Safety and tolerability were evaluated in patient populations.

Main Results:

A clear dose-response curve was observed for oral zolmitriptan.

Related Experiment Videos

Efficacy was demonstrated within 45 minutes of administration.

Zolmitriptan exhibited excellent safety and tolerability profiles in non-contraindicated patients.

Conclusions:

Zolmitriptan is an effective and well-tolerated treatment for acute migraine.
The drug offers a defined dose-response and rapid onset of action.
Ongoing development of new formulations will enhance patient treatment options.